drugset
drugset / Trial / NCT00688467

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

NCT00688467 ↗

Phase 2 Completed 19 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

Evaluation of treatment in participants with mild asthma.

Timeline

Start
2008-06-01
Primary completion
2009-03-01
Completion
2009-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject NAVARIXIN ANHYDROUS Small molecule 30 mg —

Indications

asthma